Full Press Release Details
| Investor Relations | Media Relations | |
| Bernie Hertel | Ronald Trahan, APR | |
| Inovio Biomedical Corp. | Ronald Trahan Associates, Inc. | |
| Phone: 858-410-3101 | Phone: 508-359-4005, x108 |
DNA vaccine company, Inovio Biomedical,
Punit Dhillon to Vice President of
Finance & Operations
SAN DIEGO, Calif., Jan. 30,
2008 Inovio Biomedical Corporation (AMEX:INO), a leader in
enabling the development of therapeutic DNA vaccines for cancers and infectious
diseases using its electroporation-based delivery platform, announced
today the promotion of Punit S. Dhillon to the position of Vice President of Finance
and Operations, effective immediately. He will be responsible for the
implementation of Inovio s corporate strategy, including achievement of annual
budgets and milestones.
In positions of increasing responsibilities during his past five years at
Inovio, Mr. Dhillon has played a vital role in various corporate finance
projects, including management of financing transactions, as well as day-to-day
management of operational functions. Mr. Dhillon
was most recently Executive Director of Operations and Finance.
corporate finance background, said Peter Kies, CFO, and he has been
successful in aligning our operational structure and processes to support
Inovio s corporate strategy.
We welcome Punit to our executive
management team. He has been very effective in operational management,
yielding positive results for our business, added Avtar Dhillon, MD, president and CEO. We
expect Punit to continue to play an important role in achieving our goal of
having Inovio s electroporation-based DNA delivery technology become an
indivisible element of promising DNA vaccines against cancers and infectious
Prior to joining Inovio, Mr. Dhillon
worked for a corporate finance law firm as a law clerk. He previously worked
with MDS Capital Corp. (now Lumira) and was a consultant to several early-stage
health and life science companies. Mr. Dhillon has a Bachelor of Arts,
Honors, in Political Science and a minor in Business Administration from Simon
About Inovio Biomedical Corporation
Biomedical (AMEX: INO) is a leader
in developing human applications of electroporation, using brief, controlled
electrical pulses to increase cellular uptake of a useful
biopharmaceutical. Interim human data has shown that Inovio s DNA
delivery technology can significantly increase gene expression and immune
responses from DNA vaccines. Immunotherapy partners include Merck,
Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army,
National Cancer Institute, and International Aids Vaccine Initiative. Inovio s
technology is protected by an extensive patent portfolio covering in vivo
electroporation. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results
Sorrento Valley Road San Diego,
California 92121-1318
(858) 597-6006 Fax: (858)